The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series.

Abstract

The treatment of patients with human immunodeficiency virus (HIV) infection and hemophilia involves unique challenges that may be addressed with novel antiretroviral classes. We describe the safety and efficacy of enfuvirtide therapy in 4 patients with severe hemophilia A. Although local skin reactions were common, neither local nor systemic bleeding worsened. Three patients achieved undetectable HIV loads with enfuvirtide salvage regimens.

• Authors: Mark N Polizzotto, Alison M Street, Edwina Wright
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 45 Issue 4 Pg. e39-41 (Aug 15 2007) ISSN: 1537-6591 [Electronic] United States
• PMID: 17638184 (Publication Type: Case Reports, Journal Article)

Chemical References

• HIV Envelope Protein gp41
• HIV Fusion Inhibitors
• Peptide Fragments
• Enfuvirtide

Topics

• Adult
• Enfuvirtide
• HIV Envelope Protein gp41 (adverse effects, therapeutic use)
• HIV Fusion Inhibitors (adverse effects, therapeutic use)
• HIV Infections (complications, drug therapy)
• Hemophilia A (complications)
• Humans
• Male
• Middle Aged
• Peptide Fragments (adverse effects, therapeutic use)